Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 243

1.

Do Biologic Parameters Affect the Time to First Treatment of Clinical Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia Rai Stage 0? Results of a Prospective Analysis.

Molica S, Giannarelli D, Levato L, Gentile M, Mirabelli R, Morabito F.

Clin Lymphoma Myeloma Leuk. 2014 Sep 28. pii: S2152-2650(14)00413-3. doi: 10.1016/j.clml.2014.09.003. [Epub ahead of print]

PMID:
25445470
[PubMed - as supplied by publisher]
2.

Effects of exogenous progesterone on fetal nuchal translucency: an observational prospective study.

Giorlandino C, Cignini P, Padula F, Giannarelli D, d'Emidio L, Aloisi A, Plotti F, Angioli R.

Am J Obstet Gynecol. 2014 Oct 8. pii: S0002-9378(14)01045-X. doi: 10.1016/j.ajog.2014.10.003. [Epub ahead of print]

PMID:
25305408
[PubMed - as supplied by publisher]
3.

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.

Vici P, Pizzuti L, Natoli C, Moscetti L, Mentuccia L, Vaccaro A, Sergi D, Di Lauro L, Trenta P, Seminara P, Santini D, Iezzi L, Tinari N, Bertolini I, Sini V, Mottolese M, Giannarelli D, Giotta F, Maugeri-Saccà M, Barba M, Marchetti P, Michelotti A, Sperduti I, Gamucci T.

Breast Cancer Res Treat. 2014 Oct;147(3):599-607. doi: 10.1007/s10549-014-3133-1. Epub 2014 Sep 19.

PMID:
25234842
[PubMed - in process]
Free PMC Article
4.

Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis.

Bria E, Massari F, Maines F, Pilotto S, Bonomi M, Porta C, Bracarda S, Heng D, Santini D, Sperduti I, Giannarelli D, Cognetti F, Tortora G, Milella M.

Crit Rev Oncol Hematol. 2015 Jan;93(1):50-59. doi: 10.1016/j.critrevonc.2014.08.001. Epub 2014 Aug 18. Review.

PMID:
25195095
[PubMed - as supplied by publisher]
5.

Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines.

Molica S, Giannarelli D, Mirabelli R, Levato L, Gentile M, Lentini M, Morabito F.

Expert Rev Hematol. 2014 Oct;7(5):691-5. doi: 10.1586/17474086.2014.954542. Epub 2014 Aug 31.

PMID:
25174547
[PubMed - in process]
6.

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M, Esposito A, Paone M, Palla M, Palmieri G, Caracò C, Ciliberto G, Mozzillo N, Ascierto PA.

Oncoimmunology. 2014 May 14;3:e28780. eCollection 2014.

PMID:
25083318
[PubMed]
Free PMC Article
7.

A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL).

Molica S, Giannarelli D, Levato L, Mirabelli R, Gentile M, Lentini M, Morabito F.

Int J Hematol. 2014 Sep;100(3):290-5. doi: 10.1007/s12185-014-1634-7. Epub 2014 Jul 27.

PMID:
25064370
[PubMed - in process]
8.

Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases.

Gentile M, Mauro FR, Rossi D, Vincelli I, Tripepi G, Recchia AG, De Stefano L, Campanelli M, Giannarelli D, Bossio S, Morabito L, Vigna E, Gaidano G, Foà R, Morabito F.

Br J Haematol. 2014 Oct;167(2):224-32. doi: 10.1111/bjh.13032. Epub 2014 Jul 11.

PMID:
25041609
[PubMed - indexed for MEDLINE]
9.

Features and organization of Pain Centers in the Lazio Region, Italy, in 2011.

Latina R, De Marinis MG, Baglìo G, Cattaruzza MS, Notaro P, Guzzetti V, Osborn J, Sansoni J, Giannarelli D, Piredda M, D'Angelo D, Mastroianni C, Casale G, Gatti A, Tarsitani G, Pain Centers Group PC.

Ann Ig. 2014 Jul-Aug;26(4):367-79. doi: 10.7416/ai.2014.1996.

PMID:
25001126
[PubMed - indexed for MEDLINE]
10.

Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials.

Bria E, Carbognin L, Furlanetto J, Pilotto S, Bonomi M, Guarneri V, Vicentini C, Brunelli M, Nortilli R, Pellini F, Sperduti I, Giannarelli D, Pollini GP, Conte P, Tortora G.

Cancer Treat Rev. 2014 Aug;40(7):847-56. doi: 10.1016/j.ctrv.2014.05.001. Epub 2014 May 15.

PMID:
24877987
[PubMed - indexed for MEDLINE]
11.

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

Vaccaro V, Fabi A, Vidiri A, Giannarelli D, Metro G, Telera S, Vari S, Piludu F, Carosi MA, Villani V, Cognetti F, Pompili A, Marucci L, Carapella CM, Pace A.

Biomed Res Int. 2014;2014:351252. doi: 10.1155/2014/351252. Epub 2014 May 4.

PMID:
24877084
[PubMed - in process]
Free PMC Article
12.

Reference charts for fetal corpus callosum length: a prospective cross-sectional study of 2950 fetuses.

Cignini P, Padula F, Giorlandino M, Brutti P, Alfò M, Giannarelli D, Mastrandrea ML, D'Emidio L, Vacca L, Aloisi A, Giorlandino C.

J Ultrasound Med. 2014 Jun;33(6):1065-78. doi: 10.7863/ultra.33.6.1065.

PMID:
24866614
[PubMed - in process]
13.

Evaluation of renal function under controlled hypotension in zero ischemia robotic assisted partial nephrectomy.

Forastiere E, Claroni C, Sofra M, Torregiani G, Covotta M, Marchione MG, Giannarelli D, Papalia R.

Kidney Blood Press Res. 2013;38(2-3):181-5. doi: 10.1159/000355766. Epub 2014 Apr 8.

PMID:
24732055
[PubMed - indexed for MEDLINE]
14.

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.

Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, Sandomenico F, Petrillo A, Botti G, Fulciniti F, Palmieri G, Queirolo P, Marchetti P, Ferraresi V, Rinaldi G, Pistillo MP, Ciliberto G, Mozzillo N, Ascierto PA.

Cancer Immunol Immunother. 2014 Jul;63(7):675-83. doi: 10.1007/s00262-014-1545-8. Epub 2014 Apr 3.

PMID:
24695951
[PubMed - indexed for MEDLINE]
15.

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.

Altomonte M, Di Giacomo A, Queirolo P, Ascierto P, Spagnolo F, Bajetta E, Calabrò L, Danielli R, de Rosa F, Maur M, Chiarion-Sileni V, Ferrucci P, Giannarelli D, Testori A, Ridolfi R, Maio M.

J Exp Clin Cancer Res. 2013 Oct 25;32:82. doi: 10.1186/1756-9966-32-82.

PMID:
24423086
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma.

Benedetti Panici P, Basile S, Salerno MG, Di Donato V, Marchetti C, Perniola G, Palagiano A, Perutelli A, Maneschi F, Lissoni AA, Signorelli M, Scambia G, Tateo S, Mangili G, Katsaros D, Campagnutta E, Donadello N, Greggi S, Melpignano M, Raspagliesi F, Cormio G, Grassi R, Franchi M, Giannarelli D, Fossati R, Torri V, Crocè C, Mangioni C.

Am J Obstet Gynecol. 2014 Apr;210(4):363.e1-363.e10. doi: 10.1016/j.ajog.2013.12.025. Epub 2013 Dec 19.

PMID:
24361787
[PubMed - indexed for MEDLINE]
17.

Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation.

Rossi L, Veltri E, Zullo A, Zoratto F, Colonna M, Longo F, Mottolese M, Giannarelli D, Ruco L, Marchetti P, Romiti A, Barucca V, Giannini G, Bianchi L, Tomao S.

Onco Targets Ther. 2013 Nov 29;6:1761-9. doi: 10.2147/OTT.S43828. eCollection 2013.

PMID:
24348051
[PubMed]
Free PMC Article
18.

Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials.

Pilotto S, Di Maio M, Peretti U, Kinspergher S, Brunelli M, Massari F, Sperduti I, Giannarelli D, De Marinis F, Tortora G, Bria E.

Crit Rev Oncol Hematol. 2014 May;90(2):135-45. doi: 10.1016/j.critrevonc.2013.11.005. Epub 2013 Dec 1. Review.

PMID:
24332915
[PubMed - indexed for MEDLINE]
19.

FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.

Maugeri-Saccà M, Pizzuti L, Sergi D, Barba M, Belli F, Fattoruso S, Giannarelli D, Amodio A, Boggia S, Vici P, Di Lauro L.

J Exp Clin Cancer Res. 2013 Sep 17;32:67. doi: 10.1186/1756-9966-32-67.

PMID:
24330513
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.

Di Lauro L, Vici P, Belli F, Tomao S, Fattoruso SI, Arena MG, Pizzuti L, Giannarelli D, Paoletti G, Barba M, Sergi D, Maugeri-Saccà M.

Gastric Cancer. 2014 Oct;17(4):718-24. doi: 10.1007/s10120-013-0321-3. Epub 2013 Dec 8.

PMID:
24318671
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk